• Asian Pacific Journal of Cancer Prevention
• /
• v.17 no.1
• /
• pp.255-259
• /
• 2016

Background: Reliable and validated instruments are needed in order to study the quality of life in myeloma patients. This study aimed to translate and explore the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) myeloma module (QLQ-MY20) in Iranian patients. Materials and Methods: Two hundred and fifteen patients with multiple myeloma (MM) were recruited from Imam Khomeini Hospital, Tehran. A standard forward-backward translation procedure was implemented. Participating patients were asked to complete the EORTC QLQ-C30 and the QLQ-MY20 three times, at study entry, after two weeks, and again after three months. Data were tested for the range of measurement, internal consistency, test-retest reliability, known group comparison, responsiveness and factor structure. Results: Mean age of the patients was 60.7 years. No floor and ceiling effects were seen for the QLQ-MY20. Cronbach's ${\alpha}$ was greater than 0.80 for all three multi-item scales (ranging from 0.82 to 0.93). All four scales had test-retest reliability of 0.85 or greater. Results of the confirmatory factor analysis that the hypothesized 3-scale measurement model of the QLQ-MY20. Moreover, the Persian version for the QLQ-MY20 differentiated between subgroups of the patients in terms of beta-2 microglobulin, fracture and performance status. The responsiveness of the QLQ-MY20 to change over time was confirmed within 3 months. Conclusions: the results of our study indicate that our Iranian version of the QLQ-MY20 is a feasible, reliable and valid questionnaire for assessing the condition-specific quality of life of patients with MM.

• Korean Journal of Adult Nursing
• /
• v.28 no.3
• /
• pp.314-322
• /
• 2016

Purpose: The purpose of this study was to identify the quality of life reported by patients with multiple myeloma and secondly to identify the factors that impact the quality of life (QoL). Methods: 189 patients with multiple myeloma completed survey questionnaires. Quality of life was evaluated using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C) 30 and Multiple Myeloma (MY) 20. The data were analyzed using the t-test, ANOVA, Kruskal-Wallis test, Duncan test and the Mann-Whitney test. Results: The mean score for each subscale of EORTC QLQ-C30 was 53.35 for global health status, 73.37 for functional scale, and 31.29 for symptom scale. The mean score for each subscale of EORTC QLQ-MY20 was 60.49 for future perspective, 59.78 for body image, 20.25 for disease symptom and 24.99 for side effect of treatment. Quality of life was reported to be significantly lower among females, unemployed, dependence on a sibling for financial support for treatment, a diagnosis of anemia, having treatment, high score on Eastern Coorperative Oncology Group and high grade peripheral neuropathy. Conclusion: The results of the survey can identify characteristics impacting the QoL of patients with multiple myeloma. Developing appropriate educational strategies and nursing interventions would enhance their QoL.